AMD linked to increased incidence of death from stroke, cardiovascular events

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Age-related macular degeneration (AMD) may be a useful indicator for predicting death from stroke or cardiovascular disease, according to a study published online ahead of print by the British Journal of Ophthalmology.

Jennifer S. Tan at the University of Sydney, Australia and team assessed 3654 subjects (age ≥49 years), with follow-up at five (n=2335) and 10 (n=1952) years. Assessment included physical risk factors and medical history; causes of death were confirmed by the Australian National Death Index.

Early presentation of AMD was, after adjusting for traditional cardiovascular risk factors, linked to a twofold increase in cardiovascular mortality over a 10-year period in subjects aged <75 years at baseline. Late presentation of AMD was, after adjusting for age and gender, associated with a five times increased incidence of cardiovascular mortality and a 10 times increased incidence of stroke mortality, again in subjects aged <75 years at baseline.

The researchers concluded that this association of AMD with mortality from stroke and cardiovascular events may have implications for intravitreal anti-VEGF therapies, which are also linked with an increased risk of stroke.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Archway: Phase 3 end-of-trial results show Port Delivery System is noninferior to monthly ranibizumab
Clinical trial offers insight into development of KSI-301
© 2023 MJH Life Sciences

All rights reserved.